Objectives: To determine the effects of calcium antagonists on hyperinsulinemia, hypertriglyceridemia and hypertension, we examined the long-term effects of a new calcium channel blocker, mibefradil, on plasma insulin levels, plasma triglyceride levels and Ž . systolic blood pressure in insulin-resistant and hyperinsulinemic fructose-hypertensive FH rats. To this aim, both prevention and reversal protocols were employed. Methods: PreÕention study: Male Sprague-Dawley rats were procured at 6 weeks of age and were divided Ž . Ž . Ž . Ž . into: control C, n s 6 , control-treated CT, n s 5 , fructose F, n s 7 and fructose-treated FT, n s 6 . Baseline measurements of Ž plasma glucose, insulin and systolic blood pressure were conducted in all groups. At week 7, chronic mibefradil treatment 30 . mgrkgrday, orally for 6 weeks was initiated in the CT and FT groups. At week 8, the rats in the F and FT groups were started on a 66% fructose diet to induce hyperinsulinemia and hypertension. Weekly measurements of plasma insulin, plasma triglycerides and systolic blood pressure were conducted for the following 4 weeks. ReÕersal protocol: In a separate study, 8-week-treated FH rats and their age-matched controls were used to examine the effects of mibefradil on reversing fructose-induced hyperinsulinemia and hypertension. Ž . Ž Results: The F group exhibited hyperinsulinemia 3.2 " 0.1 vs. C 2.3 " 0.07 ngrml, P -0.05 , hypertension 148 " 3 vs. C 121 " 1 . Ž . mmHg, P -0.002 and elevated triglyceride levels 5.4 " 0.8 vs. C 1.6 " 0.3 mM, P -0.05 . Chronic mibefradil treatment prevented the Ž . Ž . development of hyperinsulinemia 1.6 " 0.08 ngrml, P -0.004 vs. F and hypertension 123 " 1 mmHg, P -0.001 vs. F and attenuated the development of hypertriglyceridemia. In the reversal study, mibefradil treatment reversed the development of hyperinsu-Ž linemia, hypertriglyceridemia and elevated BP in FH rats. Treatment did not affect the plasma glucose levels in any group prevention or . reversal . Conclusions: Long-term treatment with the calcium antagonist, mibefradil, both prevents and reverses the development of hyperinsulinemia, hypertriglyceridemia and hypertension in FH rats. These data indicate beneficial effects of mibefradil on carbohydrate and lipid metabolism in hyperinsulinemic and insulin-resistant states.
Introduction
The intriguing association between insulin and hypertension has been extensively explored during the past decade. Interest in the link between insulin and high blood Ž . Ž . pressure BP was fuelled by two distinct observations: 1 the lack of effective antihypertensive drugs to reduce the increased incidence of coronary artery disease in hyperten-Ž . sive subjects and 2 the realization that essential hypertension per se is frequently associated with insulin resis-Ž . tance resistance to the glucoregulatory actions of insulin and hyperinsulinemia. These observations led to the so-) Corresponding author. Tel. q1 604 822-9373; Fax q1 604 822-8001.
called 'insulin hypothesis' of hypertension where it was postulated that insulin resistance andror hyperinsulinemia may be causally linked to the development of hypertension. This was an attractive proposition which could help explain the apparent inability of conventional antihy-Ž . pertensive drugs thiazides, beta-blockers to decrease the incidence of coronary ischemic events, since these drugs Ž did not improve but rather worsened insulin action for w x. review, see Ref. 1 .
In a series of experiments, we recently examined the proposition that insulin resistance and hyperinsulinemia contribute causally to the development of hypertension.
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Ž . PII S 0 0 0 8 -6 3 6 3 9 7 0 0 0 3 2 -1 ( )Essentially, if these defects were intrinsically linked to high BP, then agents that specifically improved insulin action should decrease BP. Indeed, we found that multiple drug interventions that exhibited the common property of Ž attenuating hyperinsulinemia metformin, the trace element . vanadium, pioglitazone lowered BP in two experimental w x models of hypertension 2,3 . Furthermore, the antihypertensive effects of these agents could be reversed by simply increasing the plasma insulin levels in the drug-treated rats to pre-treatment levels. These results indicate that there exists a strong and close association between hyperinsulinemia and hypertension in rodent models of hypertension.
In addition to drugs that specifically attenuate hyperin-Ž . sulinemia such as metformin, vanadium , recent studies indicate that insulin sensitivity is increased by several different classes of antihypertensive agents such as angiotensin-converting enzyme inhibitors, angiotensin-II receptor antagonists and peripheral alpha-adrenergic antagow x nists 4,5 . Calcium channel antagonists are used as major therapeutic agents in the treatment of systemic hypertension and ischemic heart disease; however, significant variation in their effects on carbohydrate and lipid metabolism has been reported. In contrast to diuretics and Ž . beta-blockers that worsen insulin sensitivity , calcium antagonists have generally been considered to be metaboli-Ž . cally neutral nifedipine, verapamil, diltiazem or slightly Ž . positive isradipine, pioglitazone in their effects on gluw x cose and insulin 13-17 . On the other hand, there is some debate as to whether the clinical use of these agents is associated with suppression of insulin secretion and the development of insulin resistance and diabetes mellitus w x 18-21 . Therefore, the present study was initiated to further characterize the effects of a new calcium antagonist, mibefradil, on insulin, glucose, triglycerides and systolic blood pressure in insulin-resistant and hyperinsulinemic rats.
Ž . Mibefradil Ro 40-5967 is a new calcium channel blocker that has been demonstrated to have potent antihyw x pertensive and anti-ischemic effects 6 and is currently in phase III clinical trials. Mibefradil appears to be the only calcium antagonist that completely blocks the T-type calw x cium channels 6,22-24 . Although the available calcium Ž blockers exert their effects on the L-type long-lasting, . Ž high-voltage-activated calcium channels, the T-type tran-. sient, low-voltage activated calcium channel is found in relatively high density in spontaneously active vascular muscle and may play a role in vascular hypertrophy and w x remodeling 24-27 . To our knowledge, there is no information on the effects of chronic inhibition of T-type calcium channels on carbohydrate and lipid metabolism in states of insulin resistance and hypertension, which was the objective of the present study. To this aim, the effects of chronic mibefradil treatment were studied in hyperinsulinemic, hypertensive FH rats. The FH rat model has been extensively used to study the inter-relationship between hyperinsulinemia, insulin resistance and hypertension, wherein feeding normal Sprague-Dawley rats a high fructose diet results in hyperinsulinemia, marked insulin resisw x tance, elevated triglycerides and high BP 3,5,7,12 .
Methods

Animals and experimental design
2.1.1. PreÕention protocol Ž Male Sprague-Dawley rats were procured locally 180-. 200 g body weight at 6 weeks of age. The animals were Ž divided into 4 experimental groups: control-untreated C, . Ž . n s 6 , control mibefradil-treated CT, n s 5 , fructose-un-Ž . Ž treated F, n s 7 and fructose mibefradil-treated FT, . n s 6 . After recording basal values of plasma insulin, glucose, triglycerides and systolic BP chronic mibefradil treatment was initiated in the CT and FT groups. Treatment was initiated at a concentration of 30 mgrkgrday Ž . w x p.o. via daily oral gavage as previously described 8 . One week after initiating mibefradil treatment, the animals in the F and FT groups were started on a 66% fructose Ž diet. The fructose diet 66% fructose, 12% fat and 22% . protein; Teklad Labs, Madison, WI, USA had an electrolyte, protein and fat content very comparable to the standard rat chow. Beginning at week 9, BP, plasma insulin, glucose and triglycerides were measured each Ž . week for the next 4 weeks. Insulin sensitivity IS was estimated by comparing the ratios of plasma insulin to Ž . glucose 5 h fasted in the experimental groups at week 12.
ReÕersal protocol
In this study the effects of mibefradil were examined after the development of hyperinsulinemia and hypertension in FH rats. Male Sprague-Dawley rats that had Ž been treated with fructose diet for 8 weeks and their age-. and weight-matched control rats were divided into: C Ž . Ž . Ž . Ž . ns6 , CT ns6 , F ns6 and FT n s 6 . Mibefradil Ž treatment was started in the CT and FT groups 30 . mgrkgrday p.o. via daily oral gavage for 2 weeks. Plasma glucose, insulin, triglycerides and BP were determined before and after treatment.
BP measurement
Systolic BP was measured in conscious rats using the w x indirect tail-cuff method without external preheating 28 . The animals were preconditioned to the experimental procedure before the actual measurements were conducted. In this method, the reappearance of pulsations on gradual deflation of the BP cuff are detected by a photoelectric sensor and are amplified and recorded digitally as the systolic BP. An average of 5 such readings was taken to obtain the individual systolic BP. We have validated readings obtained by this method by comparison with those ( )obtained by direct intra-arterial cannulation. Recorded Ž . pressures were similar within 5 mmHg to those obtained by direct cannulation; similar results have been reported by w x other laboratories 7,28,29 .
Biochemical measurements
Ž . Blood samples 5-h-fasted were centrifuged for 15 min Ž at 15 000 rpm using a desktop centrifuge Biofuge 17R, . model 2752, Baxter to separate plasma. Plasma samples were stored at y708C until further analyzed. Plasma glucose was measured by the glucose oxidase method, using a Ž diagnostic kit from Boehringer Mannheim Laval, Quebec, . Canada . Plasma triglycerides were determined colorimetrically using a kit from Boehringer Mannheim. Plasma insulin was assayed using a double-antibody radioimmunoassay, using a kit from Linco Research Inc. Diagnos-Ž . tics Inc. St. Louis, MO, USA using a guinea-pig anti-rat insulin antibody and rat insulin standards.
Statistical analysis
Differences among groups were evaluated using multi-Ž . variate analysis of variance MANOVA , using a Number Ž . Cruncher Statistical Program NCSS . Values are expressed as means " s.e. In this study, a probability of P -0.05 was taken to indicate a significant difference between the means. Once the MANOVA detected a significant difference in the mean vector, the individual variables were analyzed by employing the Newman-Keuls test for multiple comparisons. Comparisons of insulinrglucose Ž . ratios were done using a Student's t-test Fig. 2 . 
Results
General characteristics
The F group exhibited hyperinsulinemia and hyper-Ž tension when compared to the C group average of weeks Table 1 General characteristics of rats in the 4 experimental groups in the prevention study Avg. weeks 9-12 1.6"0. 1 is indicative of insulin resistance; we have previously demonstrated that FH rats are markedly insulin-resistant when assessed using the euglycemic hyperinsulinemic w x clamp 3 . In this study, IS was estimated by comparing the insulinrglucose ratio among groups. Using this index, the F rats exhibited a decreased IS when compared to the Ž . C group Fig. 2 . The F group also exhibited increases in Ž triglycerides when compared to the C group Table 1 , Fig.  . 
.
Effects of mibefradil treatment before the deÕelopment ( of hyperinsulinemia and hypertension in FH rats preÕen-) tion study
Chronic mibefradil treatment of the F group caused marked and sustained decreases in both plasma insulin Ž levels average of weeks 9-12: 1.6 " 0.08 ngrml, P -. Ž 0.004 vs. F, Fig. 1A and systolic BP average of weeks . 9-12: 123 " 1 mmHg, P -0.001 vs. F, Fig. 1B . This was associated with an improvement in IS in the FT group Ž . Fig. 2 . Although the drug decreased insulin levels in the Ž . CT group, it did not affect BP discussed later . Additionally, chronic mibefradil treatment attenuated the develop-Ž ment of hypertriglyceridemia in the FT group Table 1 , . Fig. 3 . 
Effects of mibefradil treatment after the deÕelopment ( of hyperinsulinemia and hypertension in FH rats reÕersal ) study
The effects of mibefradil treatment on various parameters determined in this study are described in Table 2 .
Ž . Treatment of FH rats after 8 weeks of fructose feeding reversed the elevated BP, insulin and triglyceride levels in Table 2 General characteristics of rats in the 4 experimental groups in the reversal study the FT group. Treatment had no effect on the glucose levels in either study.
Discussion
This is the first report to demonstrate that the antihypertensive effects of a specific T-type calcium channel blocker, mibefradil, are associated with sustained and marked re- ( )ductions in plasma insulin and improvement in IS. The treatment was effective in lowering the triglyceride levels in FT rats in both the prevention and reversal protocols employed. These data indicate that mibefradil exhibits beneficial effects on carbohydrate and lipid metabolism in addition to its antihypertensive effects. Several mechanisms have been proposed to link hyperinsulinemia to hypertension including insulin-induced antinatriuresis, stimulation of the sympathetic nervous system, alterations in calcium transport systems and insulin-media-Ž . Ž ted alterations in vascular smooth muscle VSM tone for w x. review, see Ref. 1 . Of these mechanisms, interest has w x focused on the action of insulin on the VSM 9 . Recent reports indicate that insulin may attenuate the contractile responses to a variety of vasoactive agents and cause w x decreases in VSM tone and reactivity 11 . This has led to the hypothesis that in states of insulin resistance, insulininduced vasodilation may be blunted, which may contribute to the development or maintenance of elevated BP w x 9 . In support of this view, we have recently found that insulin-mediated attenuation of vasoactive responses to angiotensin II are blunted in insulin-resistant FH rat aortae w x 30 .
Interestingly, a decrease in plasma insulin levels in the control-mibefradil-treated rats did not cause a decrease in BP in the prevention study. The question arises as to why hyperinsulinemia causes hypertension in insulin-resistant rats without doing so in insulin-sensitive control animals. One possibility is that insulin-sensitive tissues would in-Ž crease glucose utilization in response to the increase in . insulin levels , which may initiate vasodilatory responses in order to increase local blood flow. By contrast, insulin w x resistance could blunt such vasodilatory effects 30 . As stated in the earlier paragraph, in support of this we have recently demonstrated that insulin attenuates the vasoconstrictor effects of angiotensin II in control rat arteries; w x however, this effect is blunted in FH rats 30 . As altered blood flow in resting muscle is considered to represent a possible factor responsible for the development of insulin resistance, it is possible that in insulin-sensitive cases the insulin-glucose system may respond to the vasodilation evoked by calcium channel blockers in a different way from insulin-resistant hypertensive states vs. the former w x control situation 35 .
As discussed earlier, multiple drug interventions that possess insulin-sensitizing properties lead to concurrent w x decreases in plasma insulin levels and BP in FH rats 1 . By contrast, diverse antihypertensive-vasodilator agents Žangiotensin-receptor blockers, peripheral alpha antago-. nists, angiotensin-converting enzyme inhibitors have also been shown to improve insulin sensitivity and decrease w x plasma insulin levels 4,5 . In the former case, the antihypertensive effects of insulin sensitizers have been attributed to their ability to counter hyperinsulinemia and Ž . thereby correct the hypertensinogenic mediator s linking Ž . insulin to BP discussed above . On the other hand, the ability of vasodilator-antihypertensive agents to increase insulin sensitivity may be an indirect consequence of drug-induced vasodilation and hence an increased blood w x flow to insulin-sensitive tissues 10 . On the basis of these observations, it has been speculated that some common Ž mechanism such as increases in intracellular VSM cal-. cium may underlie both the expression of insulin resisw x tancerhyperinsulinemia and vasoconstriction 10 . Thus, on the one hand, insulin resistance results in vasoconstriction, while on the other hand vasoconstriction results in decreases in blood flow to insulin target tissues, which further worsens insulin resistance. As discussed elegantly w x by Kotchen 10 , if the cycle is interrupted by agents that directly improve insulin sensitivity or by vasodilators that improve blood flow, the final outcome is an improvement in insulin sensitivity, a decrease in plasma insulin levels and a decrease in BP. A diagrammatic representation of this hypothesis is presented in Fig. 4 . Fig. 4 . Hypothetical model linking insulin resistance, vascular smooth muscle tone and elevated blood pressure.
( )An issue that merits attention are studies that have associated calcium channel antagonists with the development of diabetes, impaired glucose tolerance and insulin resistance, presumably through blocking calcium-induced w x insulin secretion 18-21 . However, the balance of published work suggests that at hemodynamically active doses, they do not normally interfere with insulin release nor w x impair glucose tolerance in man 31-33 . This is further supported by animal studies that report that calcium channel blockers inhibit insulin secretion in vitro but not in w x vivo 18 . Comparative studies indicate that diltiazem, verapamil, nifedipine and flunarizine are neutral towards w x carbohydrate metabolism 31 , while the calcium channel blocker, pioglitazone, markedly attenuates the developw x ment of hyperinsulinemia in rats 17 . By marked contrast, LAS 30538 markedly inhibits insulin secretion in vivo w x 31 . Thus, to reach a general consensus regarding the effects of calcium antagonists on insulin sensitivity is difficult as the effects vary depending on the agent investigated.
If one assumes that the beneficial effects of vasodilators Ž compounds ACE inhibitors, angiotensin II antagonists, . peripheral alpha antagonists on insulin sensitivity lie in their ability to increase skeletal muscle blood flow and counter insulin resistance, then it is difficult to construe why there is such marked variation in the effects of calcium channel antagonists on insulin sensitivity. The current data on dihydropyridine-type calcium channel Ž . w x blockers e.g., nifedipine is conflicting 37,38 while the non-dihydropyridine derivative calcium antagonists Ž . verapamil, diltiazem appear to neither improve nor w x worsen insulin sensitivity in essential hypertension 15,37 . wŽ . Ž Ž Ž It is important to note that mibefradil 1S,2 S -2 2-3-be-. . . . nzimidazolyl propyl methyl-amino ethyl -6-fluoro-1,2,3,4-tetrahydro-1-isopropyl-2-naphthyl methoxyacetate dihydrox chloride represents a novel non-dihydropyridine calcium channel blocker that binds to the same site as verapamil, yet does not reduce myocardial force in either normal or w x diseased hearts 22,23 . It appears to be the only calcium antagonist that completely blocks the T-type calcium channels. Thus, it is possible that the unique pharmacological properties of this compound may distinguish it from other calcium antagonists; however, this remains to be determined.
The discussion of the insulin hypothesis of hypertension cannot be complete without highlighting the relationship between hyperinsulinemia and the sympathetic nervous system. Although hyperinsulinemia causes marked sympathetic activation, it paradoxically attenuates the vasoconw x strictor effects in vitro and causes vasodilation in vivo 39 . Preliminary studies from our research group have evaluated the role of the sympathetic nervous system in modulating FH in rats. Interestingly, we have observed that Ž removing the sympathetic influence by chemical sympa-. thectomy completely obliterates the development of both w x hyperinsulinemia and hypertension in fructose-fed rats 36 .
Furthermore, sympathectomy restores the ability of insulin Ž to regulate vascular smooth muscle tone S. Verma, S. Bhanot, L. Yao, I. Laher and J. McNeill, unpublished . observations, September 1996 . These data suggest that an intricate relationship exists linking hyperinsulinemia, insulin resistance, elevated sympathetic discharge, and the Ž vascular effects of insulin in states of hypertension inde-. Ž . pendent of obesity . Given the complexity of mechanism s and their interdependence, the dissection of cause and effect is difficult; however, it is possible that the beneficial effects of mibefradil may be secondary to a decrease in sympathetic nervous system activity and a correction of the aforementioned pathways.
It may be argued that the effects of mibefradil on plasma insulin levels are secondary to inhibition of calcium channels in the pancreatic beta cells and a reduction in insulin secretion. As discussed earlier, in vitro studies do demonstrate that calcium antagonists may inhibit pancreatic insulin release; however, this effect does not appear to occur in vivo at hemodynamically effective doses. Furthermore, if mibefradil were to decrease insulin release, it would in turn lead to hyperglycemia, which was not the case in either the CT or FT groups. Thus, it is reasonable to suggest that the effects of the drug on insulin levels were independent of changes in pancreatic insulin release.
Finally, a recent report on fructose-induced hypertension has documented an interesting finding that deserves mention. The study deals with the effects of dietary fructose versus dietary magnesium deficiency in the etiology of hypertension in this model. The authors hypothesize that it was the magnesium deficiency in the fructose diet w x that lead to fructose-induced insulin resistance 34 . The fructose diet is reasonably matched for sodium and potas-Ž sium with control rat chow but is low in magnesium one . third of control chow . The authors reported that when rats were fed a high fructose diet that had a magnesium content similar to that present in normal rat chow, the rats did not develop insulin insensitivity or an increase in BP. This was in contrast to the rats fed the conventional fructose diet, who did exhibit insulin resistance, hyperinsulinemia and hypertension. Although insulin sensitivity was assessed by Ž the hindquarter perfusion method which is not an accurate . measure of in-vivo insulin sensitivity , the results were interesting, especially since several recent reports suggest that magnesium deficiency may cause insulin resistance. In our experiments, the fructose diet was deficient in magnesium and since serum magnesium levels were not measured, we cannot rule out the possibility that dietary magnesium deficiency could be partlyrfully responsible for causing insulin resistance in fructose-fed rats. However, regardless of the mechanism causing insulin resistance in FH rats, the consequent metabolic and hemodynamic abnormalities that occur are prevented by both insulin sensiw x tizers and vasodilators this study . Furthermore, results w x from our insulin implant studies 2,3 clearly indicate that insulin resistance, hyperinsulinemia and hypertension are ( )very closely related in these rats. Therefore, the findings from the present study mentioned above do not contradict the hypothesis in any way but rather shed light on one of the possible mechanisms underlying the severe insulin insensitivity observed in FH rats.
In summary, the present study is the first report of long-term administration of a T-type calcium channel blocker in hyperinsulinemic, insulin-resistant and hypertensive rats. Chronic mibefradil treatment of FH rats both prevents and reverses the development of hyperinsulinemia, hypertriglyceridemia and elevated BP. Whether the decrease in insulin levels is due to a direct effect of mibefradil to improve insulin sensitivity or is secondary to an improvement in blood flow to insulin target tissues, is an important question that needs to be further examined. As a large number of essential hypertensive subjects have Ž defects in carbohydrate and lipid metabolism that fail to . respond to conventional therapy , further experimental and clinical studies documenting the beneficial effects of mibefradil on these parameters merit attention.
